Previous 10 | Next 10 |
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses PR Newswire BERWYN, Pa. , Feb. 1, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clin...
Summary Today, we take our first look at Annovis Bio, Inc. which has given its shareholders a rollercoaster ride since the company went public in 2020. The company is advancing its primary drug candidate into late-stage development to potentially treat both Alzheimer's and Parkinson's d...
Annovis Bio ( NYSE: ANVS ) said it had begun patient enrollment for its ongoing Phase 3 study of its drug, buntanetap, to treat Parkinson's disease. The company expects interim data analysis from the study in the second quarter. Patients are being treated with 10mg, 20mg of th...
Clinical stage biotech Annovis Bio ( NYSE: ANVS ) traded higher in the morning hours Wednesday after the company highlighted "strong" patient enrollment in its Phase 3 trial for Parkinson's disease (PD) candidate buntanetap. "We are very pleased with the pace of enrollment in our Phas...
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE PR Newswire Strong enrollment in Phase 3 trial demonstrates continued execution Interim analysis expected in 2Q 2023 BERWYN, Pa. , J...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team PR Newswire BERWYN, Penn. , Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurod...
Annovis Bio press release ( NYSE: ANVS ): Q3 GAAP EPS of -$0.93 beats by $0.08 . Cash, cash equivalents, and marketable securities were $32M as of September 30, 2022. For further details see: Annovis Bio GAAP EPS of -$0.93 beats by $0.08
Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update PR Newswire BERWYN, Penn. , Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing ...
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference PR Newswire BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative dise...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...